Early-stage COVID-19 Vaccine Trial Begins
in Singapore
Around 100 people will take part in the clinical trial of the Lunar-Cov19 vaccine developed by Duke-NUS Medical School and United States pharmaceutical company Arcturus Therapeutics, which is set to last until October. This vaccine involves a newer type of biotechnology, training the body to recognise a key part of the virus - the spike protein - without exposing it to the whole virus.
The vaccine had shown promising pre-clinical results, and the next step would be to ensure it is safe, and that it can elicit a robust antibody and T-cell immunity in vaccinated individuals to confer long-lasting protection against COVID-19.
|
 |
| Covid-19: Stories from SingHealth |
|
Defending Against COVID-19 in the Dormitories
"Everyone went the extra mile to creatively support the well-being and welfare of the dormitory residents, and I was moved and inspired by the compassion and humanity I witnessed," shares Ms Lim Soo Ting, Senior Nurse Clinician and Advanced Practice Nurse at KK Women's and Children's Hospital.
Frontline Perspective: Nurse Educator
Nurse Educator Anuradha Ramasamy describes her experience stepping up to perform N95 mask fittings for hospital staff at the beginning of the pandemic, and adapting to conducting training programmes online.
|
|
|
|
